BIVI BioVie
- 0.501
- +0.006+1.13%
BioVie News
BioVie | 10-Q: Quarterly report
BioVie Awarded up to $13.1 Million in Funding From U.S. Department of Defense to Evaluate Bezisterim (NE3107) for the Treatment of Long COVID
Increasing evidence supports a role for viral persistence, chronic inflammation and immune and metabolic dysregulation in driving long COVID Bezisterim, an anti-inflammatory and insulin-sensitizer that permeates the
BioVie Secures $13.1M Funding From US Department of Defense for Long COVID Treatment | NASDAQ:BIVI
BioVie Presents Data Showing Potential For Bezisterim To Reduce Inflammation And Restore Homeostasis In A Manner Correlated With Alzheimer's Disease And Biomarker Endpoints
"Bezisterim" has been approved as the non-proprietary name for NE3107Data shows how bezisterim may be restoring homeostasis via specific genes associated with dementia, metabolism, and inflammationCAR
BioVie Presents Data Showing Potential for Bezisterim (NE3107) to Reduce Inflammation and Restore Homeostasis in a Manner Correlated With Alzheimer's Disease and Biomarker Endpoints
Data shows how bezisterim may be restoring homeostasis via specific genes associated with dementia, metabolism, and inflammation
BioVie Presents New Data Showing Lead Drug Asset May Promote Healthier Aging | NASDAQ:BIVI
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
GainersImmutep (NASDAQ:IMMP) stock increased by 15.5% to $2.9 during Wednesday's pre-market session. The market value of their outstanding shares is at $344.7 million. Syra Health (NASDAQ:SYRA) stock
BioVie to Present Data Showing How NE3107 Potentially Restores Homeostasis via Specific Genes Associated With Dementia, Metabolism, and Inflammation
CARSON CITY, Nev., April 18, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI), ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and
Genetic Technologies and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / April 12, 2024 / RedChip Companies will air interviews with Genetic Technologies Limited and BioVie, Inc. on the RedChip Small Stocks, Big Money show, a
12 Health Care Stocks Moving In Monday's After-Market Session
GainersOpGen (NASDAQ:OPGN) shares moved upwards by 24.0% to $0.74 during Monday's after-market session. The market value of their outstanding shares is at $7.4 million. Galecto (NASDAQ:GLTO) shares in
BioVie Says Recently Completed Funding Round Provides Opportunity To Further Its Clinical Priorities In Parkinson's Disease, Alzheimer's Disease, And Ascites/Liver Disease, The Company Continues To Explore Longevity And Aging In Conjunction With Partners
BioVie Says Recently Completed Funding Round Provides Opportunity To Further Its Clinical Priorities In Parkinson's Disease, Alzheimer's Disease, And Ascites/Liver Disease, The Company Continues To Ex
Press Release: BioVie Announces Pipeline Update and Near-Term Clinical Priorities
BioVie Inc., (NASDAQ: BIVI) ("BioVie" or the "Company") a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that its recently completed funding round provides opportunity to further the Company's clinical priorities in Parkinson's Disease (PD), Alzheimer's Disease (AD), and ascites/liver disease.
BioVie Strengthens Capital With $21M Public Offering
BioVie Inc. Announces Closing of Public Offering
CARSON CITY, Nev., March 06, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI), ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions
Renalytix RNLX Potential Buyer; BioVie BIVI Offering
Crude Oil Down Over 1%; Quoin Pharmaceuticals Shares Spike Higher
U.S. stocks traded lower toward the end of trading, with the S&P 500 edging lower on Monday. The Dow traded down 0.20% to 39,007.30 while the NASDAQ fell 0.18% to 16,245.77. The S&P 500 also fell, dro
Top Midday Decliners
BioVie (BIVI) shares slumped after the company said Monday it plans to raise $21 million from a securities sale. The stock tumbled 43% as intraday volume topped 12.8 million shares versus the daily av
Update: BioVie Prices $21 Million Offering of Shares, Warrants; Stock Slumps
(Updates with stock price movement in the headline and the first paragraph) BioVie (BIVI) shares were down about 43% in recent Monday trading following its plan to raise $21 million from securities sa
JAGX, BBAI and BNTC Among Mid-day Movers
Gold Gains 1%; JOANN Shares Plummet
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling around 0.2% on Monday. The Dow traded down 0.25% to 38,988.86 while the NASDAQ fell 0.18% to 16,245.30. The S&P 500 a
Analysis
Price Target
No Data
